FDA's New Rules: Checking if Pills Play Nice with Pregnancies
Published Date: 5/11/2026
Notice
Summary
The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
New Method Guidance: Registries & Rare Exposures
The final guidance updates methods for postapproval pregnancy safety work by clarifying the pregnancy registry section (including a new statistical methods subsection), broadening complementary study methods, expanding discussion on collecting data when rare exposures are expected, and updating terminology to include descriptive pregnancy safety studies. These methodological updates affect how sponsors and investigators design and document postapproval pregnancy safety investigations.
Final FDA Guidance for Pregnancy Safety Studies
On May 11, 2026 the FDA published a final guidance called "Postapproval Pregnancy Safety Studies" that gives recommendations to drug sponsors and investigators on how to design studies that assess safety outcomes in pregnant women after a drug or biologic is approved. The guidance finalizes a draft originally issued on May 9, 2019 and is available to industry and investigators for immediate use.
Guidance Is Non-Binding and Deregulatory
FDA states the guidance reflects its current thinking but is not binding; sponsors may use alternative approaches if they meet statute and regulation requirements. FDA also assessed this action as an Executive Order 14192 deregulatory action and the guidance contains no new collections of information under the Paperwork Reduction Act.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-09267, Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers create medicines that treat, prevent, or stop Clostridioides difficile infections (CDI) from coming back. This update affects companies working on CDI drugs and aims to speed up safe, effective treatments reaching patients. The guidance is official as of May 11, 2026, and could save time and money by clarifying what’s needed for drug approval.
Next: 2026-09269, Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability
The FDA just released final guidance to help drug makers create new medicines to treat lung tuberculosis (TB). This update affects companies developing TB drugs by clarifying how to test and prove their treatments work safely and effectively. The guidance is official as of May 11, 2026, aiming to speed up better TB treatments without extra costs for the public.